Arlington, MA, United States of America

Kenneth Egnard Lind

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals Limited. Active years: 2014-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth Egnard Lind. Retrieved from https://idiyas.com/inventor/kenneth-egnard-lind

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 


Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Location History:

  • Belmont, MA (US) (2014)
  • Arlington, MA (US) (2018)

Company Filing History:


Years Active: 2014-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Kenneth Egnard Lind: Innovator in Cancer Treatment

Introduction

Kenneth Egnard Lind is a notable inventor based in Arlington, MA, who has made significant contributions to the field of cancer treatment. With a total of two patents to his name, Lind's work focuses on innovative methods that aim to improve therapeutic outcomes for cancer patients.

Latest Patents

Lind's latest patents include groundbreaking inventions related to pyridinonyl PDK1 inhibitors. The first patent outlines methods of treatment using these inhibitors, which are designed to target and treat cancer effectively. The second patent further elaborates on the same inhibitors and their application in cancer treatment, showcasing Lind's commitment to advancing medical science.

Career Highlights

Throughout his career, Kenneth Egnard Lind has worked with prominent companies in the pharmaceutical industry. He has been associated with Sunesis Pharmaceuticals, Inc. and Millennium Pharmaceuticals Limited, where he has contributed to the development of innovative cancer therapies.

Collaborations

Lind has collaborated with several talented individuals in his field, including Kathy Jingyuan Cao and Edward Yin-Shiang Lin. These collaborations have likely enriched his research and contributed to the success of his inventions.

Conclusion

Kenneth Egnard Lind's work in developing pyridinonyl PDK1 inhibitors represents a significant advancement in cancer treatment. His contributions to the pharmaceutical industry and collaborations with other professionals highlight his dedication to improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…